vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and TRUSTCO BANK CORP N Y (TRST). Click either name above to swap in a different company.

TRUSTCO BANK CORP N Y is the larger business by last-quarter revenue ($49.5M vs $38.3M, roughly 1.3× ImmunityBio, Inc.). TRUSTCO BANK CORP N Y runs the higher net margin — 32.9% vs -161.8%, a 194.7% gap on every dollar of revenue.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

TRUSTCO BANK CORP N Y is a regional U.S. financial holding company that provides a full suite of retail and commercial banking products and services, including personal deposit accounts, mortgage loans, small business financing, and wealth management solutions. It primarily operates across New York, Florida, and several other U.S. states, serving individual consumers and small business client segments.

IBRX vs TRST — Head-to-Head

Bigger by revenue
TRST
TRST
1.3× larger
TRST
$49.5M
$38.3M
IBRX
Higher net margin
TRST
TRST
194.7% more per $
TRST
32.9%
-161.8%
IBRX

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IBRX
IBRX
TRST
TRST
Revenue
$38.3M
$49.5M
Net Profit
$-61.9M
$16.3M
Gross Margin
99.0%
Operating Margin
-169.0%
Net Margin
-161.8%
32.9%
Revenue YoY
407.0%
Net Profit YoY
-4.7%
14.1%
EPS (diluted)
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
TRST
TRST
Q1 26
$49.5M
Q4 25
$38.3M
$48.2M
Q3 25
$32.1M
$47.8M
Q2 25
$26.4M
$46.6M
Q1 25
$16.5M
$45.3M
Q4 24
$7.6M
$43.3M
Q3 24
$6.1M
$43.6M
Q2 24
$43.4M
Net Profit
IBRX
IBRX
TRST
TRST
Q1 26
$16.3M
Q4 25
$-61.9M
$15.6M
Q3 25
$-67.3M
$16.3M
Q2 25
$-92.6M
$15.0M
Q1 25
$-129.6M
$14.3M
Q4 24
$-59.2M
$11.3M
Q3 24
$-85.7M
$12.9M
Q2 24
$12.6M
Gross Margin
IBRX
IBRX
TRST
TRST
Q1 26
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Operating Margin
IBRX
IBRX
TRST
TRST
Q1 26
Q4 25
-169.0%
43.7%
Q3 25
-173.5%
44.6%
Q2 25
-269.8%
42.3%
Q1 25
-390.1%
41.3%
Q4 24
-919.0%
34.0%
Q3 24
-1314.3%
38.8%
Q2 24
37.9%
Net Margin
IBRX
IBRX
TRST
TRST
Q1 26
32.9%
Q4 25
-161.8%
32.3%
Q3 25
-209.8%
34.0%
Q2 25
-350.3%
32.3%
Q1 25
-784.9%
31.5%
Q4 24
-783.4%
26.0%
Q3 24
-1404.0%
29.5%
Q2 24
28.9%
EPS (diluted)
IBRX
IBRX
TRST
TRST
Q1 26
Q4 25
$-0.06
$0.85
Q3 25
$-0.07
$0.86
Q2 25
$-0.10
$0.79
Q1 25
$-0.15
$0.75
Q4 24
$-0.08
$0.59
Q3 24
$-0.14
$0.68
Q2 24
$0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
TRST
TRST
Cash + ST InvestmentsLiquidity on hand
$242.8M
Total DebtLower is stronger
$112.9M
Stockholders' EquityBook value
$-500.5M
$670.9M
Total Assets
$501.9M
$6.5B
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
TRST
TRST
Q1 26
Q4 25
$242.8M
$730.4M
Q3 25
$257.8M
$695.6M
Q2 25
$153.7M
$713.6M
Q1 25
$61.6M
$756.1M
Q4 24
$149.8M
$641.8M
Q3 24
$130.4M
$523.0M
Q2 24
$536.1M
Total Debt
IBRX
IBRX
TRST
TRST
Q1 26
$112.9M
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
IBRX
IBRX
TRST
TRST
Q1 26
$670.9M
Q4 25
$-500.5M
$686.6M
Q3 25
$-524.3M
$692.0M
Q2 25
$-570.7M
$692.8M
Q1 25
$-591.4M
$687.8M
Q4 24
$-489.1M
$676.3M
Q3 24
$-745.1M
$669.0M
Q2 24
$655.2M
Total Assets
IBRX
IBRX
TRST
TRST
Q1 26
$6.5B
Q4 25
$501.9M
$6.4B
Q3 25
$519.0M
$6.3B
Q2 25
$402.1M
$6.3B
Q1 25
$303.8M
$6.3B
Q4 24
$382.9M
$6.2B
Q3 24
$364.6M
$6.1B
Q2 24
$6.1B
Debt / Equity
IBRX
IBRX
TRST
TRST
Q1 26
0.17×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
TRST
TRST
Operating Cash FlowLast quarter
$-70.4M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
TRST
TRST
Q1 26
Q4 25
$-70.4M
$57.6M
Q3 25
$-68.9M
$12.8M
Q2 25
$-79.7M
$27.1M
Q1 25
$-85.9M
$1.3M
Q4 24
$-85.1M
$59.4M
Q3 24
$-98.8M
$16.5M
Q2 24
$18.7M
Free Cash Flow
IBRX
IBRX
TRST
TRST
Q1 26
Q4 25
$-71.3M
$45.7M
Q3 25
$-69.6M
$10.0M
Q2 25
$-80.8M
$24.9M
Q1 25
$-87.0M
$-3.3M
Q4 24
$-87.3M
$54.6M
Q3 24
$-101.6M
$15.6M
Q2 24
$17.6M
FCF Margin
IBRX
IBRX
TRST
TRST
Q1 26
Q4 25
-186.2%
95.0%
Q3 25
-217.2%
20.9%
Q2 25
-305.9%
53.5%
Q1 25
-526.9%
-7.2%
Q4 24
-1155.4%
126.0%
Q3 24
-1663.2%
35.7%
Q2 24
40.5%
Capex Intensity
IBRX
IBRX
TRST
TRST
Q1 26
Q4 25
2.4%
24.6%
Q3 25
2.3%
5.9%
Q2 25
4.1%
4.5%
Q1 25
6.8%
10.0%
Q4 24
28.0%
11.3%
Q3 24
45.7%
2.1%
Q2 24
2.6%
Cash Conversion
IBRX
IBRX
TRST
TRST
Q1 26
Q4 25
3.70×
Q3 25
0.79×
Q2 25
1.80×
Q1 25
0.09×
Q4 24
5.27×
Q3 24
1.28×
Q2 24
1.49×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBRX
IBRX

Segment breakdown not available.

TRST
TRST

Net Interest Income$44.7M90%
Noninterest Income$4.8M10%

Related Comparisons